Ospemifene is a novel, oral selective estrogen receptor modulator that has been approved in the USA for treatment of dyspareunia. The decline in estrogen during menopause creates vulvovaginal changes that can cause symptoms that adversely impact women psychosexually. Many women are reluctant to discuss painful sex and providers must proactively inquire about sexuality issues. Ospemifene has been shown to reverse changes associated with vulvovaginal atrophy and relieve symptoms of dyspareunia. Safety studies of treatment up to 52 weeks have shown ospemifene to be safe with no impact on endometrial hyperplasia/carcinoma, venous thrombotic events or pelvic organ prolapse. Further studies are needed to evaluate its role in bone and breast health.
Papers of special interest have been highlighted as:
2.
of interest; •• of considerable interest
3.
SantoroNKomiJ. Prevalence and impact of vaginal symptoms among postmenopausal women. J. Sex. Med.6, 2133–2142 (2009).
4.
LevineKBWilliamsREHartmannKE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause15, 661–666 (2008).
5.
KingsbergSAWysockiSMagnusLKrychmanML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal women's Views of Treatment options for menopausal vaginal changEs) survey. J. Sex. Med.10, 1790–1799 (2013).
6.
SturdeeDWPanayN. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric13, 509–522 (2010).
7.
ElkinsonSYangLPH. Ospemifene: first global approval. Drugs73, 605–612 (2013).
8.
The North American Menopause Society. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause15(4), 584–602 (2008).
9.
The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause20(3), 888–902 (2013).
10.
Key overview of state of the art management of vulvovaginal atrophy.
11.
BachmannGBouchardCHoppeDEfficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. Menopause16(4), 719–727 (2009).
12.
LongCYLuCMHsuSCWuCHWangCLTsaiEM. A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vasculature and sexual function in hysterectomized postmenopausal women. Menopause13, 737–743 (2006).
13.
PinkertonJVStanczykFZ. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy. Menopause21(3), 1–11 (2014).
14.
Excellent review of selective estrogen receptor modulators and vaginal atrophy.
15.
SoeLHWurzGTKaoCJDeGregorioMW. Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast. Int. J. Womens Health5, 605–611 (2013).
16.
KangasLUnkilaM. Tissue selectivity of ospemifene: pharmacologic profile and clinical implications. Steroids78, 1273–1280 (2013).
17.
Osphena®, prescribing package insert. Shionogi Inc., NJ, USA.
18.
US FDA-approved package insert.
19.
KoskimiesPTurunenJLammintaustaRScheininM. Single-dose and steady-state pharmacokinetics of ospemifene, a selective estrogen receptor modulator, in postmenopausal women. Int. J. Clin. Pharmacol. Ther.51(11), 861–867 (2013).
20.
GoldsteinSRBachmannGAKoninckxPRLinVHPortmanDJ, Ylikorkala O, and The Ospemifene Study Group. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric17, 173–182 (2014).
21.
Ospemifene (Osphena) for dyspareunia. Med Lett. Drugs Ther.55(1420), 55–56 (2013).
22.
BachmannGAKomiJO; The Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal Phase 3 study. Menopause17, 480–486 (2010).
23.
SimonJALinVHRadovichCBachmannGA; The Ospemifene Study Group. One year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause20(4), 418427 (2013).
24.
SimonJPortmanDMabeyRGJr; The Ospemifene Study Group. Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women. Maturitas77(3), 274–281 (2014).
25.
PortmanDJBachmannGASimonJA; The Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause20(6), 1–8 (2013).
26.
KomiJLankinenKSHarkonenPEffects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women. Menopause12(2), 202–209 (2005).
27.
RutanenEMHeikkinenJHalonenKKomiJLammintaustaRYlikorkalaO. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women. Menopause10(5), 433–439 (2003).
28.
WurtzGTSoeLHDeGregorioMW. Ospemifene, vulvovaginal atrophy, and breast cancer. Maturitas74, 220–225 (2013).
29.
QuQZhengHDahlundJSelective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology141(2), 809–820 (2000).
30.
KomiJHeikkinenJRutanenEMEffects of ospemifene, a novel SERM on biochemical markers of bone turnover in healthy postmenopausal women. Gynecol. Endocrinol.18 (3), 152–158 (2004).
31.
KomiJLankinenKSDeGregorioMEffects of ospemifene and raloxifene on biochemical markers of bone turnover in post-menopausal women. J. Bone Miner. Metab.24 (4), 314–318 (2006).
32.
FreemanEWSherifK. Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric10, 197–214 (2007).
33.
LabrieFArcherDFBouchardCIntravaginal dehyrdroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric14, 282–288 (2011).
34.
JonassonAFEdwallLUvnas-MobergK. Topical oxytocin reverses vaginal atrophy in postmenopausal women: a double-blind randomized pilot study. Menopause Int.17(4), 120–125 (2011).
